The Worldwide Stem Cell Therapy Industry is Projected to Reach $401 Million by 2026 at a CAGR of 16.5% from 2021 – PRNewswire

DUBLIN, May 14, 2021 /PRNewswire/ -- The "Global Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) - Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.

The global stem cell therapy market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% during the forecast period.

Growth in this market is majorly driven by the increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.

The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, by type, during the forecast period

The stem cell therapy market is segmented into allogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. The large share of this segment can be attributed to the lesser complexities involved in manufacturing allogeneic-based therapies.

This segment is also expected to grow at the highest growth rate due to the increasing number of clinical trials in manufacturing allogeneic-based products.

Bone Marrow-derived MSCs segment accounted for the highest CAGR

Based on the cell source from which stem cells are obtained, the global stem cell therapy market is segmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which include human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines).

The bone marrow-derived MSCs segment is expected to witness the highest growth rate during the forecast period, owing to an increasing number of clinical trials focused on bone marrow-derived cell therapies and the rising demand for these cells in blood-related disorders.

Asia Pacific: The fastest-growing country in the stem cell therapy market

The stem cell therapy market is segmented into North America, Europe, Asia Pacific, RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period.

Factors such as the growing adoption of stem cell-based treatment in the region and the growing approval & commercialization of stem cell-based products for degenerative disorders drive the growth of the stem cell therapy market in the region.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights4.1 Stem Cell Therapy Market Overview4.2 North America: Stem Cell Therapy Market4.3 Stem Cell Therapy Market, by Cell Source4.4 Stem Cell Therapy Market: Geographic Growth Opportunities

5 Market Overview5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Availability of Funding for Stem Cell Research5.2.1.2 Increasing GMP-Certification Approvals for Cell Therapy Production Facilities5.2.1.3 Increasing Clinical Trials for Stem Cell Based-Therapies5.2.2 Restraints5.2.2.1 Ethical Concerns Related to Embryonic Stem Cells5.2.2.2 High Cost of Cell-Based Research5.2.3 Opportunities5.2.3.1 The Emergence of IPSCs as an Alternative to ESCs5.2.3.2 Growing Demand for Cell & Gene Therapies5.2.4 Challenges5.2.4.1 Technical Limitations5.3 COVID-19 Impact Analysis5.4 Technology Analysis5.5 Value Chain Analysis5.6 Ecosystem Market Map5.7 Supply Chain5.8 Porters Five Forces Analysis5.8.1 Threat of New Entrants5.8.2 Threat of Substitutes5.8.3 Bargaining Power of Suppliers5.8.4 Bargaining Power of Buyers5.8.5 Intensity of Competition Rivalry5.9 Regulatory Landscape5.9.1 North America5.9.2 Europe5.9.3 Asia-Pacific5.9.4 Row5.10 Pricing Analysis5.11 Patent Analysis

6 Stem Cell Therapy Market, by Type6.1 Introduction6.2 Allogeneic Stem Cell Therapy6.2.1 Ease in Production Processes to Drive Market Growth6.3 Autologous Stem Cell Therapy6.3.1 Low Risk of Post-Treatment Complications to Drive the Market Growth

7 Stem Cell Therapy Market, by Cell Source7.1 Introduction7.2 Adipose Tissue-Derived MSCs7.2.1 Advantages of Being Easy to Isolate and Harvest Drives the Market Growth of this Segment7.3 Bone Marrow-Derived MSCs7.3.1 Increasing Cases of Metabolic Disorders to Support Market Growth of this Segment7.4 Placenta/Umbilical Cord-Derived MSCs7.4.1 Low Chances of Rejection from the Immune System is Likely to Support Market Growth of this Segment7.5 Other Cell Sources

8 Stem Cell Therapy Market, by Therapeutic Application8.1 Introduction8.2 Musculoskeletal Disorders8.2.1 Increasing Cases of Osteoarthritis to Drive the Market Growth of this Segment8.3 Wounds & Injuries8.3.1 Increasing Benefits of Allogeneic-Based Therapies to Support the Market Growth8.4 Inflammatory & Autoimmune Diseases8.4.1 Increasing Clinical Trials for this Segment is Likely to Support Market Growth8.5 Surgeries8.5.1 Increasing Clinical Research for Surgical Applications to Support Market Growth8.6 Cardiovascular Diseases8.6.1 Increasing Public & Private Funding for CVD Research is Likely to Support Market Growth8.7 Neurological Disorders8.7.1 Rising Prevalence of Neurogenerative Disorders Supports Market Growth of this Segment8.8 Other Therapeutic Applications

9 Stem Cell Therapy Market, by Region9.1 Introduction9.2 North America9.3 Europe9.4 Asia-Pacific9.5 Rest of the World

10 Competitive Landscape10.1 Overview10.2 Revenue Share Analysis of Top Market Players10.3 Market Share Analysis10.4 Competitive Leadership Mapping10.4.1 Stars10.4.2 Emerging Leaders10.4.3 Pervasive Players10.4.4 Participants10.5 Stem Cell Therapy Market: SME Evaluation Matrix, 2020 (Under Pipeline)10.5.1 Progressive Companies10.5.2 Starting Blocks10.5.3 Responsive Companies10.5.4 Dynamic Companies10.6 Company Product Footprint10.7 Company Geographic Footprint of Major Players in the Stem Cell Therapy Market10.8 Competitive Scenario10.8.1 Product Launches10.8.2 Deals10.8.3 Other Developments

11 Company Profiles11.1 Major Players11.1.1 Smith & Nephew11.1.2 Medipost11.1.3 Anterogen11.1.4 Corestem11.1.5 Pharmicell11.1.6 NuVasive11.1.7 RTI Surgical11.1.8 AlloSource11.1.9 JCR Pharmaceuticals11.1.10 Takeda Pharmaceutical Company11.1.11 Holostem Terapie Avanzate11.1.12 Orthofix11.1.13 Stempeutics Research11.1.14 Regrow Biosciences11.2 Other Players (Under Pipeline)11.2.1 Athersys11.2.2 Mesoblast11.2.3 BioRestorative Therapies11.2.4 Pluristem Theraputics11.2.5 Brainstorm Cell Therapeutics11.2.6 Gamida Cell11.2.7 ViaCyte11.2.8 Kangstem Biotech11.2.9 Hope Biosciences11.2.10 Cellular Biomedicine Group11.2.11 Personalized Stem Cells

12 Appendix12.1 Discussion Guide12.2 Knowledge Store: The Subscription Portal12.3 Available Customizations

For more information about this report visit https://www.researchandmarkets.com/r/s3mud8

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Originally posted here:

The Worldwide Stem Cell Therapy Industry is Projected to Reach $401 Million by 2026 at a CAGR of 16.5% from 2021 - PRNewswire